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24 ABSTRACT
25 Background: Alexander disease, an autosomal dominant leukodystrophy, is caused by 
26 missense mutations in GFAP. Although mostly diagnosed in children, associated with severe 
27 leukoencephalopathy, milder adult forms also exist.
28 Methods: A family affected by adult-onset spastic paraplegia underwent neurological 
29 examination and cerebral MRI. Two patients were sequenced by WES. A candidate variant was 
30 functionally tested in an astrocytoma cell line.
31 Results: The novel variant in GFAP N-terminal head domain (p.Gly18Val) cosegregated in 
32 multiple relatives (LOD score: 2.7). All patients, even those with the mildest forms, showed 
33 characteristic signal changes or atrophy in the brainstem and spinal cord MRIs, and abnormal 
34 MRS. In vitro, this variant did not cause significant protein aggregation, in contrast to most 
35 Alexander disease mutations characterized so far. However, cell area analysis showed larger 
36 size, a feature previously described in patients and mouse models.
37 Conclusion: We suggest that this variant causes variable expressivity and an attenuated 
38 phenotype of Alexander Disease type II, probably associated with alternative pathogenic 
39 mechanisms, i.e. astrocyte enlargement. GFAP analysis should be considered in adult-onset 
40 neurologic presentations with pyramidal and bulbar symptoms, in particular when characteristic 
41 findings, such as the tadpole sign, are present in MRI. WES is a powerful tool to diagnose 
42 atypical cases.
43 Keywords: “Alexander disease”, “GFAP”, “WES”, “astrocyte hypertrophy”
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45 INTRODUCTION
46 Missense gain-of-function mutations in GFAP are the only known cause of Alexander disease, a 
47 rare neurodegenerative disorder pathologically defined by white matter degeneration and the 
48 presence of characteristic Rosenthal fibres (intracytoplasmic inclusions in astrocytes).1, 2 In 
49 infantile cases (Alexander Disease type I), patients present developmental delay, macrocephaly, 
50 seizures and progressive encephalopathy, leading to death within the first decade. MRI shows 
51 leukoencephalopathy without brainstem abnormalities.3 Later-onset cases (Alexander Disease 
52 type II) present wide phenotypic variability, with symptoms such as ataxia, spastic paraparesis, 
53 palatal tremor, abnormal ocular movements, and bulbar or pseudobulbar symptoms.4 Additional 
54 neurologic signs such as dysautonomia, urinary disturbances and sleep disorders are often 
55 described.5 Atypical features, including scoliosis, mild cognitive deficit, parkinsonism, seizures, 
56 peripheral neuropathy or microcoria, have been reported.6-8 MRI shows little cerebral white 
57 matter involvement and is characterized by atrophy and signal intensity changes in the 
58 brainstem.9
59 Although most GFAP mutations occur de novo, adult-onset Alexander disease has also been 
60 described in familial cases with autosomal dominant transmission.7 In this work, we report a 
61 family affected by ocular movement abnormalities and mild signs of pyramidal involvement, in 
62 which a rare variant of the GFAP gene was found by whole exome sequencing (WES). Based 
63 on clinical data and functional studies, we suggest that this variant is less deleterious than the 
64 vast majority of Alexander disease mutations, giving rise to an attenuated clinical phenotype.
65 RESULTS
66 A 46-year-old Caucasian woman (Figure 1, patient II:3) presented with a 2-year history of 
67 spasticity and lower limb weakness. Cranial and cervical MRI was initially reported as normal. 
68 She denied a history of neurological disease in her family, except for a maternal cousin (patient 
69 II:5), who had "gait problems”. She also mentioned that her 16-year-old son (patient III:4) had 
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70 frequent falls and mild difficulties in running starting at 9 years old, similar to her cousin’s son 
71 (patient III:5). After ruling out acquired causes we tested spastic paraparesis genes (SPG3, 
72 SPG4, SPG10 and SPG11) and ABCD1 gene (X-linked adrenomyeloneuropathy), with negative 
73 results. Genetic tests for hereditary ataxias were also negative. In a final attempt to elucidate this 
74 disease, we included the family in a research protocol and carried out WES on patients II:5 and 
75 III:4. WES analysis revealed 5 rare variants shared by both patients. Only one variant 
76 cosegregated in all 4 affected relatives (II:3, II:5, III:4 and III:5); an heterozygous missense 
77 variant in the GFAP gene, p.Gly18Val. Mutations in this gene cause Alexander disease (OMIM 
78 #203450), an autosomal dominant leukodystrophy with described adult presentations.1, 4 This 
79 variant was not previously associated with Alexander disease, nor was it present in databases of 
80 control individuals (1000 Genomes, ExAC, and gnomAD). Segregation analysis indicated that 
81 this variant was also carried by two asymptomatic family members (I:2 and II:2). We therefore 
82 decided to clinically re-evaluate all family members and found abnormalities in ocular 
83 movements and pyramidal involvement in both two patients. In conclusion, this family showed 
84 variable disease expressivity among 4 patients exhibiting clear signs of disease and 2 
85 paucisymptomatic individuals who presented alterations in neurological examination but had no 
86 complaints nor symptoms (patients I:2 and II:2). The age of clinical onset ranged from 9 to 46 
87 years, and age at diagnosis ranged from 16 to 73 years. Clinical findings are summarized in 
88 Supplemental Table 1, and Supplemental Video 1 shows movement abnormalities in patient 
89 III:5.
90 In patients II:3, II:5, III:4 and III:5, symptoms at disease onset included asymmetric proximal 
91 lower limb weakness due to pyramidal involvement, which was associated with proximal upper 
92 limb weakness in patient II:5. All four subjects had gait difficulties due to spastic paraparesis. 
93 Patients II:3 and II:5, aged 49 and 48 years old at first examination, needed unilateral support to 
94 walk. Patients II:3 and II:5 referred urinary disturbances; urodynamic study of patient II:3 
95 confirmed detrusor overactivity. All patients showed abnormalities in ocular movement, with 
96 gaze-evoked nystagmus without ptosis, diplopia or alterations in saccadic pursuit; brisk tendon 
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97 reflexes/hyperreflexia; extensor plantar responses; and Hoffman sign. Patients II:2, II:3, III:4 
98 and III:5 presented mild scoliosis. 
99 An exhaustive MRI re-evaluation of patient II:3 revealed signal changes and medullar atrophy. 
100 Brain and spinal cord MRI study were then extended to patients II:2, II:5, III:4 and III:5. All 
101 patients showed a mild signal change in T2/FLAIR sequences in the brainstem, specifically in 
102 the medulla and cervical spinal cord. This is illustrated by MRI images of patient II:3, in which 
103 signal change is visible in midbrain (Figure 1B), medulla (Figure 1C) and the spinal cord 
104 (Figure 1D). Furthermore, patients II:3, II:5, III:4 and III:5 showed the characteristic “tadpole 
105 sign”: some degree of atrophy of the cerebellum, medulla and spinal cord with a well-preserved 
106 pontine base, markedly characteristic of Alexander disease (illustrated in Figure 1E).10 The 
107 paucisymptomatic Patient II:2, had no atrophy, nor tadpole sign, but showed signal change in 
108 the medulla and spinal cord (Figure 1F, 1G). MR Spectroscopy was carried out in patients II.2, 
109 II.3, II.5, and III.4, with voxels centered in the area of signal and morphologic abnormality. All 
110 patients showed highly elevated levels of myo-inositol and choline with a decreased total N-
111 acetyl-aspartate in the ponto-medullary junction (Figure 1H, 1I, Supplemental Figure 1), a 
112 feature described in Alexander Disease.11,12 Radiological findings are summarized in 
113 Supplemental Table 2 and illustrated in Figure 1 and Supplemental Figure 1.
114 This GFAP gene variant (chr17:42992802C>A GRCh37; NM_001131019: c.53G>T; 
115 p.Gly18Val), found in all affected family members, was located in GFAP’s N-terminal head 
116 domain, which plays an important role in self-assembly process.13 This is the most N-terminal 
117 variant ever described. However, this residue is not strongly conserved in evolution, missense 
118 predictors were not conclusive, and no other pathogenic variants are known in the vicinity. 
119 When considering all genotyped individuals, this variant reached a maximum LOD score of 2.7 
120 (odds of ~500 to 1 supporting linkage of this locus to the disease). By applying the American 
121 College of Medical Genetics (ACMG) criteria for variant interpretation to assess this nucleotide 
122 change14, we reached a classification of VUS (Variant of Unknown Significance), and thus 
123 decided to functionally validate this variant using a transfection assay to test the capacity of the 
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124 GFAP protein carrying p.Gly18Val to induce protein aggregation in the astrocytoma cell line 
125 U251-MG (Supplemental methods).15, 16 We utilized two GFAP-EGFP control constructs, one 
126 containing the wild-type GFAP sequence, and the second incorporating the p.Arg239Cys 
127 mutation, a widely used positive control for GFAP protein aggregation. As described elsewhere, 
128 transfection of the WT construct showed large inclusions in ~20% of transfected cells17, 18, both 
129 after 24h or 48h of transfection. Cells transfected with the p.Arg239Cys-mutated construct 
130 showed the same large inclusions, but also dot-like clumps or aggregates, as reported 15, 16, 
131 which in some cases were distributed around the cell and in other cases converged and formed 
132 large aggregates near the cell nucleus, in particular at 48h after transfection (Figure 2A). In 
133 contrast, after transfecting the p.Gly18Val-mutant construct we did not observe aggregates 
134 similar to the p.Arg239Cys construct, but rather, cells showed an aspect comparable to WT 
135 cells, but with lesser inclusions (Supplemental Figure 2A, 2B). This effect was more clear at 
136 shorter transfection times (24h) or lower amounts of construct (1µg) (Figure 2A). Interestingly, 
137 in the p.Gly18Val condition we observed abnormally large cell sizes, with long astrocytic 
138 processes, a phenotype which was confirmed by quantitative image analysis (Figure 2B).
139 DISCUSSION
140 We present a family affected by a dominantly inherited neurological disease, characterized by 
141 mild to moderate late-onset cerebellar and pyramidal signs, showing signal abnormalities or 
142 atrophy in the brainstem and spinal cord, in whom we identified a candidate variant in GFAP 
143 using WES, segregating even in asymptomatic individuals. Clinical re-evaluation of all family 
144 members combined with functional validation of the novel variant ultimately led to a definitive 
145 diagnosis of familial Alexander disease type II.
146 Clinically, Alexander disease type II presents with cerebellar ataxia, pyramidal involvement, 
147 bulbar symptoms and palatal tremor. It is accompanied by variable MRI findings, although most 
148 cases  present the “tadpole sign” .10 In this family, four patients showed clear signs of cerebellar 
149 dysfunction, with mild ataxia, alteration of ocular movements and spastic paraparesis with 
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150 hyperreflexia and extensor plantar responses, and two patients were paucisymptomatic, 
151 presenting mild alterations in neurological examination, namely, scoliosis, nystagmus, diplopia, 
152 hyperreflexia and the Babinski sign. MRI images of all symptomatic patients showed notable 
153 atrophy of the spinal cord and medulla, in contrast to what was observed in the less affected 
154 patients, who presented mild signal changes in the trunk and less atrophy. We nonetheless wish 
155 to emphasize that all patients except one (patient II:2) presented the previously mentioned 
156 tadpole sign. Moreover, MRS on patients II.2, II.3, II.5, and III.4 showed a metabolite profile 
157 suggesting hypertrophy of astrocytes as previously discussed 11, consistent with neuroaxonal 
158 degeneration.12 This underscores our in vitro findings showing size enlargement of astrocytes. 
159 Indeed, no dot-like clumps or protein aggregates were found for the p.Gly18Val GFAP 
160 construct in our functional study, in contrast to most other pathogenic variants described in the 
161 literature.7,15 We also detected lesser inclusions than the WT construct, in particular when 
162 transfected with lesser amounts of plasmid. However, we detected an increased size in 
163 p.Gly18Val-transfected cells when compared to the WT and p.Arg239Cys constructs. Astrocyte 
164 hypertrophy is a known consequence of GFAP mutations in Alexander disease, as observed in 
165 mouse models and patient’s necropsies.19, 20 It is possible that astrocyte hypertrophy has been 
166 historically overlooked for other mutations in vitro due to the strong specificity of GFAP 
167 aggregates. We thus propose considering astrocyte hypertrophy as an additional criterion of 
168 pathogenicity in the functional evaluation of unreported variants.
169 Although we did not have access to brain biopsies from these patients, the absence of strong 
170 pathological signs in MRI and milder clinical manifestations in this family are compatible with 
171 the results of the aggregation assay for p.Gly18Val. This expansion of the clinical spectrum of 
172 Alexander disease suggests that other adult-onset neurologic cases with overlapping ataxia and 
173 pyramidal involvement may be caused by pathogenic GFAP variants. Therefore, screening of 
174 this gene would be recommended in presence of those symptoms and abnormal findings in 
175 MRI, even when these are subtle. An exhaustive and systematic clinical exploration of family 
176 members with milder forms or an absence of overt symptoms is recommended, since it may 
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177 lead to the identification of clinically unnoticed cases. This work underscores the usefulness of 
178 WES to identify paucisymptomatic or atypical cases, and proposes its implementation as first-
179 tier test for neurogenetic conditions with adult presentations, with the goal of improving disease 
180 management and genetic counselling.
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264 Figure 1: Family tree and genotype data for the p.Gly18Val variant and brain and 
265 cervical MRI and MRS of patients II.3 and II:2.  
266 (A) Family tree and genotype data for the p.Gly18Val variant. Square: male; circle: female; 
267 diagonal black line:deceased; black-filled  symbol: affected individual; white-filled symbol: 
268 clinically healthy; question mark: unknown status; syringe symbol: blood sampled individual; 
269 asterisk: individual sequenced by Whole Exome Sequencing (WES). p.Gly18Val/+ stands for 
270 the presence of the p.Gly18Val variant in the heterozygous state, +/+ stands for the absence of 
271 this variant in the studied individual. (B-E): Brain MRI images of patient II:3, symptomatic. (B-
272 C): Axial fluid-attenuated inversion recovery (FLAIR) shows signal change in midbrain  (B, 
273 arrow) and Subpial enhacement in medulla (C, arrow). (D): Sagittal fluid-attenuated inversion 
274 recovery (FLAIR) sequence shows spinal cord signal change and atrophy. (E): T1-weighted 
275 sagittal section shows the typical tadpole sign, with mild atrophy of medulla and cervical spinal 
276 cord  and sparing the pons. (F-G): Brain MRI of patient II:2, paucisymptomatic, who presents 
277 with subtile signs of piramidal and bulbar involvement but no complaints. (F): Sagittal fluid-
278 attenuated inversion recovery (FLAIR) sequence and (G): Sagittal T2-weighted sequence show 
279 absence of atrophy of the brainstem, but  demonstrates spinal cord signal change. (H-I): Mean 
280 spectra of Proton MRS of Patients II:2, II:3, II:5, III:4 in the medulla-cord junction, at short 
281 (30ms, Image H) and long (136ms, Image I) TE. Images show high myoinositol (MYO) and 
282 choline (CHO) in contrast to low N-acetylaspartate (NAA).
283 Figure 2: Absence of aggregates and cell area enlargement in GFAP-EGFPGly18Val-
284 transfected U251-MG cells.
285 A) Images showing transfected U251-MG cells. Green: EGFP fluorescence; red: GFAP; yellow: 
286 merged images showing colocalization with EGFP and GFAP in transfected cells. Blue 
287 indicates DAPI staining. In the second column, magnifications are shown in the lower right 
288 corner. B) Representative confocal microscopy images (63x) show U251-MG astrocytoma cells 
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289 transfected with vectors expressing GFAP-EGFPWT, GFAP-EGFPArg239Cys, or GFAP-
290 EGFPGly18Val. In the p.Gly18Val image, two representative enlarged transfected cells are shown. 
291 The cell area of the transfected cells is shown as a box plot. Error bars indicate the standard 
292 deviations of two independent experiments. ***, p<0.001. Green: GFAP-EGFP; blue: DAPI; 
293 yellow outlining: area considered for cell area measurement.
294 Supplemental Material Video 1: Presence of mild abnormalities in ocular movements 
295 (nystagmus) in patient III:5 (paucisymptomatic).
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Figure 1: Family tree and genotype data for the p.Gly18Val variant and brain and cervical MRI and MRS of 
patients II.3 and II:2. 
162x162mm (300 x 300 DPI) 
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Figure 2: Absence of aggregates and cell area enlargement in GFAP-EGFPGly18Val-transfected U251-MG 
cells. 
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SUPPLEMENTARY METHODS 
Detailed clinical studies 
Blood cell counts, routine blood biochemical analysis, clotting measurement, thyroid function 
testing, autoantibody screening, and treponemal serology were performed. Levels of anti-
glutamic decarboxylase, anti-human T-lymphotropic virus-I antibodies, anti-human 
immunodeficiency virus antibodies, ceruloplasmin, copper, very-long-chain fatty acids, vitamin 
B12 and folic acid were measured. Needle electromyography (abductor digiti minimi, spinalis 
thoracis and tibialis anterior muscles), surface antidromic sensory (sural and median nerves) and 
orthodromic motor (median, tibial or peroneal nerves) nerve conduction studies were obtained 
in all patients with an electromyography machine (Synergy, CareFusion, San Diego, CA 92130, 
EEUU). Genetic testing of the most strongly affected patients (II:3 and II:5) was performed by 
Sanger sequencing and MLPA for the most common causes of spastic paraparesis (SPG3, 
SPG4, SPG10 and SPG11), Sanger sequencing for X-linked adrenomyeloneuropathy (ABCD1, 
together with analysis of very-long-chain fatty acid levels), as well as dynamic expansion 
analysis in genes associated to spinocerebellar ataxia (1, 2, 3, 6, 7, 8, 10, 14, and 17), DRPLA, 
and Friedrich’s ataxia, with negative outcome. 
Radiological assessment 
In patients II:2, II:3, II:5, III:4 and III:5, a brain and spinal cord MRI scan was performed. Brain 
MRI protocol included T1 and T2 weighted, fluid attenuated inversion recovery (FLAIR) and 
diffusion- weighted imaging (DWI) sequences in the sagittal and axial planes. Spinal cord MRI 
protocol included T1 and T2 weighted and short tau inversion recovery (STIR) sequences in the 
sagittal and axial planes. All the exams were obtained indistinctly on a 1.5T or 3T scanner. MRI 
examinations were read by an unblinded neuroradiologist. A systematic evaluation of 
periventricular signal changes, the periventricular rim of decreased T2 signal and increased T1 
signal, brainstem enhancement or signal change, brainstem atrophy, spinal cord atrophy, spinal 
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cord enhancement and signal change, cerebellar enhancement and signal change, "tadpole 
atrophy" of the brainstem with relative sparing of pons, ependymal nodularity and thalamic or 
basal ganglia signal abnormality was performed. 
Short and long TE single voxel 1H MR spectroscopy (PRESS sequence, short TE=30ms, long 
TE=136ms) was performed for patients II:2, II:3, II:5 and III:2. The voxel was positioned on a 
three-dimensional FLAIR image centered in the area of signal and morphologic abnormality in 
the medulla/ cord-medulla junction. These exams were all acquired on a 3T scanner. 
Molecular studies 
Blood samples were obtained with informed consent. Genomic DNA was extracted from 
peripheral blood using standard methods. WES was performed on two patient DNA samples 
using the SureSelect XT Human All Exon V5 50 Mb kit (Agilent) for DNA capture and 
sequencing with the HiSeq 2000 Platform (Illumina) at CNAG (Centre Nacional d’Anàlisi 
Genòmica, Barcelona). We prioritized non-synonymous coding variants that had a frequency 
lower than 0.001 in the ExAC, 1000 genomes, and gnomAD databases and were present in both 
patients. Candidate variants were validated and tested for cosegregation in all available family 
members by Sanger sequencing. The logarithm of odds (LOD) score was calculated with the 
MERLIN package using the variant genotype as entry data. 
Human GFAP full-length cDNA (NM_002055.4) was amplified by PCR excluding the stop 
codon using an MGC Human GFAP Sequence-Verified cDNA vector as a template (MHS6278-
202757583, Dharmacon™) with primers incorporating EcoRI (forward) and BamHI (reverse) 
restriction sites. cDNA was cloned into the pEGFP-N3 vector (Clontech) upstream of the EGFP 
cDNA sequence, generating a GFAP-EGFP fusion cDNA in which EGFP was fused to the C-
terminus of GFAP. A recurrent Alexander disease mutation used as a positive control 
(p.Arg239Cys) and the p.Gly18Val mutation were introduced through site-directed mutagenesis 
(QuikChange™ kit, Agilent) using the wild-type GFAP-EGFP fusion vector as a template. All 
constructs were checked by Sanger sequencing. 
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The U-251 MG human astrocytoma cell line (Sigma-Aldrich) was maintained in DMEM 
(Gibco, Life Tech.) supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/mL 
streptomycin in a cell incubator at 5% CO2, 25°C. Cells were seeded into 6-well plates to 90% 
confluence in 24 h. Transfections were performed using 1 or 4 μg of GFAP-EGFP fusion vector 
(wild type (WT), p.Arg239Cys or p.Gly18Val) and 3 μl Lipofectamine 2000 per well (Life 
Tech.) diluted in Opti-MEM I medium (GibcoTM-ThermoFisher). After transfection for 3 
hours, cells were cultured for 24 or 48 h and then fixed in 4% PFA. For colocalization studies, 
immunocytochemistry was performed using Polyclonal Rabbit Anti-Glial Fibrillary Acidic 
Protein Z0334 antibody (1/500, Dako) and Goat Anti-Rabbit IgG Alexa Fluor 555 A-21428 
(1/1000, Dako). DAPI was used to stain cell nuclei. 
Confocal microscopy images were acquired with a Leica TCS SL laser scanning confocal 
spectral microscope using a 63x objective. To analyse GFAP networks and aggregates in detail, 
a 4x zoom was used. Cell area was determined with ImageJ via analysing GFAP-EGFP 
fluorescence by using the “Analyse particles” tool. A minimum number of 40 cells was 
analysed per genotype and condition. Statistical significance was evaluated by a one-sided 
ANOVA test, followed by post hoc Tukey’s test. 
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Supplemental Table 1. Clinical Findings 
 
 I:2 II:2 II:3 II:5 III:4 III:5 
Sex F F F F M M 
Age of onset NA NA  46 17 10 9 
Age of diagnosis 73 49 50 40 16 12 
Nystagmus + + + + + + 
Spasticity - - + + + + 
Hyperreflexia + + + + + + 
Babinski sign + + + + + + 
Hoffman sign - + + + + + 
Gait abnormality + + + + + + 
Weakness - - + + + + 
Bladder dysfunction - - + + - - 
Scoliosis - + + - + + 
Palatal tremor - - - - - - 
Dysarthria /  dysphagia - - - - - - 
Dysautonomia - - - - - - 
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Supplemental Table 2. Radiological Findings 
 
Case II:2  II:3 II:5 III:4 III:5 
White Matter 
Changes 
No No No No No 
Periventricular 
Rim (T2 signal 
decreased/ T1 
signal increased) 








Medulla Medulla Medulla 









Spinal Cord Signal 
Change 



























No No No No  No 





No No No  No 
Ependymal 
Nodularity 
No No No No No 
Thalamic / Basal 
Ganglia 
abnormality 
No No No No No 
 
 
* :  Atrophy of medulla and cervical cord with sparing pons 
+ :  Posterior periaqueductal 
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Supplemental Image 1: Proton MRS of Patients II:2, II:3, II:5, III:4 in the medulla-cord 
junction. First column: short TE (30ms). Second column: long TE (136ms).  
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Supplemental Figure 2: GFAP inclusions or aggregates in U251-MG transfected cells. In 
blue: DAPI staining; Green: EGFP fluorescence. Transfection was carried out with 1 or 4 µg of 
plasmid per well (6-well plate), and pictures were taken 48h after. A) While WT and 
p.Gly18Val –transfected cells show GFAP-EGFP protein inclusions, p.Arg239Cys-transfected 
cells (positive control of aggregation) show the presence of little dot-like clumps or aggregates.. 
B) Quantification of GFAP inclusions in transfected U251-MG cells. Data are expressed as 
mean ± s.d. One-way ANOVA was performed, followed by post-hoc Tukey’s test. 
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